A recent Supreme Court decision addressing the False Claims Act holds important implications for medical device companies, according to Gibson Dunn attorneys John D. W. Partridge, Jonathan M. Phillips and Reid F. Rector in this guest column.
John D. W. Partridge, a partner at Gibson Dunn, focuses on internal investigations, regulatory inquiries, corporate compliance programs, and complex commercial litigation. He has particular experience with...
The federal False Claims Act (FCA) is the government’s primary tool for policing alleged health-care fraud and abuse. For many medical device companies, the risks and costs associated with the...
The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.
States and international regulatory bodies may increase their US enforcement role following federal staff cuts, Hyman Phelps & McNamara attorneys said in a recent webinar. The attorneys also expect False Claims Act enforcement and public health to remain key areas of focus at the federal level.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
